Media coverage about Alliqua Biomedical (NASDAQ:ALQA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alliqua Biomedical earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave news headlines about the company an impact score of 43.9730192977196 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Separately, ValuEngine raised shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st.
NASDAQ:ALQA remained flat at $$2.02 during trading hours on Thursday. 84 shares of the company’s stock traded hands, compared to its average volume of 63,901. Alliqua Biomedical has a 52 week low of $1.58 and a 52 week high of $4.60. The firm has a market cap of $10.01 million, a P/E ratio of -0.31 and a beta of 0.94.
Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.